Transforming HIV Treatment
AETERNAVIR™ is a first-in-class dual-payload antiretroviral–immunotherapeutic platform engineered using the Synergistic Compatibility Framework (SCF) to address the most persistent challenge in HIV medicine: eliminating viral reservoirs while restoring immune control.
Conventional antiretroviral therapies successfully suppress viral replication but require lifelong treatment because latent reservoirs remain intact. AETERNAVIR™ introduces a new therapeutic model designed to target viral persistence and immune dysfunction simultaneously, opening a pathway toward long-term viral remission and potential functional cure strategies.
The AETERNAVIR™ Innovation
Dual-Payload Therapeutic Architecture
AETERNAVIR™ integrates two coordinated therapeutic mechanisms into a unified pharmacologic platform:
Component | Role | Function |
Indevirate | Antiviral payload | Blocks HIV integrase, preventing viral genome integration |
Glymorisulfonin | Immunotherapeutic payload | Reprograms immune-lymphatic signaling to destabilize viral reservoirs |
Chronobiologic Carrier System | Delivery architecture | Synchronizes pharmacokinetics and systemic tolerance |
This architecture enables simultaneous antiviral suppression and immune restoration, addressing the two major barriers preventing HIV cure.
Engineered with the Synergistic Compatibility Framework (SCF)
AETERNAVIR™ was designed using the Synergistic Compatibility Framework, an advanced drug engineering system that optimizes therapeutic synergy across five key principles:
- Targeted Drug Action – Precision targeting of disease pathways
- Pharmacokinetic Optimization – Enhanced stability and bioavailability
- Metabolic Efficiency – Selective delivery and activation
- Resistance Prevention – Multi-target therapeutic pressure
- Safety Profile Optimization – Reduced systemic toxicity
These principles guide the design of multi-component therapeutics to ensure maximal efficacy with controlled safety profiles.
A New Paradigm in HIV Therapeutics
From Viral Suppression to Functional Cure Potential
Traditional HIV therapy controls viral replication but does not eliminate integrated viral DNA. AETERNAVIR™ introduces a three-layer therapeutic strategy:
1. Viral Genome Arrest
High-barrier integrase blockade prevents new viral integration events.
2. Reservoir Destabilization
Immune-lymphatic modulation exposes latent viral reservoirs.
3. Immune Surveillance Restoration
Reprogrammed immune signaling restores long-term viral control.
This integrated approach targets the underlying mechanisms that maintain chronic HIV infection.
Designed for Next-Generation Clinical Development
AETERNAVIR™ is structured as a regulatory-aligned therapeutic development program with a defined pathway toward clinical translation.
Development Objectives
- Reservoir reduction and immune restoration
- Long-term viral remission without continuous ART
- Reduced resistance risk through multi-mechanistic action
The development program is aligned with the FDA Investigational New Drug (IND) pathway, enabling progression through Phase I safety trials followed by efficacy-focused clinical studies.
Strategic Advantages
Platform Innovation
- First-in-class dual-payload antiretroviral-immunotherapy
- Reservoir-targeting therapeutic design
- High resistance barrier architecture
- SCF-engineered synergy optimization
- Chronobiology-aligned delivery system
Clinical Impact Potential
- Reduced treatment burden for patients
- Long-term viral remission strategies
- New therapeutic category within HIV medicine
Partnership Opportunities
SCF BIOTECH Systems Therapeutics is actively seeking collaboration with:
- Biopharmaceutical companies
- Clinical research organizations
- Academic translational research groups
- Strategic life science investors
Potential collaboration models include:
- Co-development partnerships
- Platform licensing agreements
- Joint clinical research programs
- Strategic investment partnerships
About SCF BIOTECH Systems Therapeutics
SCF BIOTECH Systems Therapeutics develops next-generation therapeutics using the Synergistic Compatibility Framework, a systems-based drug engineering platform integrating molecular pharmacology, systems biology, and precision therapeutic design.
Our mission is to develop transformational therapies for complex diseases through advanced multi-mechanistic drug architectures.
AETERNAVIR™
Advancing the Future of HIV Therapeutics
Explore collaboration opportunities with SCF BIOTECH Systems Therapeutics to accelerate the development of next-generation HIV treatments.